Dementia therapy · Oncology drugs · Prescription medicines
Eisai
Eisai is a major Japanese drugmaker known for the Alzheimer's treatment Leqembi. Nikkei 225 constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
Business categories Pharmaceuticals & Biotechnology · Biopharma & Life Sciences · primary
4523.T Updated Jul 11, 2026 5 AI consumers· 2 recurring
Annual return · 2026-10-09'21-22.9%'22+42.2%'23-10.9%'24-32.2%'25-3.5%YTD+10.3%
Money in ▸·
Eisai~¥740B
▸ Money out·
Financials & Segments
- Total revenue · ~¥740B (FY2024)
- Segments · Neurology (dementia) · Oncology · Other pharmaceuticals
Revenue from
No refined links yet.
Pays to
No refined links yet.